

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) of Sheet

Complete if Known				
Application Number	10/037,791			
Filing Date	January 3, 2002			
First Named Inventor	Stanley M. Crain			
Group Art Unit	1614			
Examiner Name	James H. Reamer			
	96700/727			
		_		

Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	1	Request for Ex Parte Reexamination of U.S. Patent No. RE 36,547.	
•	2	Request for Ex Parte Reexamination of U.S. Patent No. 5,767,125.	
	3	Request for Ex Parte Reexamination of U.S. Patent No. 5,580,876.	
# · · · · · · · · · · · · · · · · · · ·	4	Request for Ex Parte Reexamination of U.S. Patent No. 6,362,194	.,
	5	Request for Ex Parte Reexamination of U.S. Patent No. 6,096,756.	
	6	Dum and Herz, 1981, "In vivo Receptor Binding of the Opiate Partial Agonist, Buprenorphine, Correlated with its Agonistic and Antagonistic Actions," Br. J. Pharmac. 74:627-633.	
	7	1(4):993-1011.	
	8	Goodman & Gilman, 1975, The Pharmacological Basis of Therapeutics, 5th Edition, Macmillan, New York, Chapter 15, p. 273.	
	9	Crain & Shen, 1995, Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic co-treatment. Proc. Natl Acad. Sci. U.S.A. 1995 Nov. 7;92(23):10540-10544.	e
	10	Konieczko et al. 1988, "Antagonism of morphine-induced respiratory depression with nalmefene," Br. J. Anaesth. 61:318-323.	

Examiner	Date
Signature	Considered
Cidilataro	the state of act in conforman

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Substitute for form 1449B/PTO

Sheet

of

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. control number.

Complete if Known 10/037,791 Application Number INFORMATION DISCLOSURE January 3, 2002 Filing Date Stanley M. Crain STATEMENT BY APPLICANT First Named Inventor 1614 **Group Art Unit** James H. Reamer Examiner Name (use as many sheets as necessary) 96700/727 Attorney Docket Number

	, ,	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	T <sup>2</sup>
Examiner Initials	Cite No.1	item (book, magazine, journal, serial, symposium, catalog, etc.), data page (c.), data of	Ļ.
initials	11	Barsan et al. 1989, "Duration of Antagonistic Effects of Nalmefene and Naloxone in Opiate-induced Sedation for Emergency Department Procedures," J. Emerg. Med. 7(2);	
	12	Abu-Elheiga et al. 2001, "Continuous fatty acid oxidation and reduced fat storage in mice lacking Acetyl-coA carboxylase 2," Science 291:2613-16.	
	13	Edition, Macmillan, New York, Chapter 19, 14th Lefte and W.P. Martin) nages 245-283.	. *
No. 1 . W. S. W. S. HOLLE	14	Budd K., 1985, "The use of the opiate antagonist, naloxone, in the treatment of intractable pain." Neuropeptides. 5(4-6):419-22.	
	15	Attal et al. 1989, "Behavioural evidence for a bidirectional effect of systemic naloxone in a model of experimental neuropathy in the rat." Brain Res. 494(2):276-84.	
	16	Kayser et al. 1981, "Dose-dependent analgesic and hyperalgesic effects of systemic naloxone in arthritic rats." Brain Res. 226(1-2):344-8.	
	17	Kayser et al. 1984, "Further evidence for a bidirectional effect of naloxone on the pain threshold in tolerant and non-tolerant arthritic rats." Neuropeptides. 5(1-3):49-52.	_
	11	Malaise & Franchimont, 1987, "Methods of clinical and biological assessment of rheumatoid arthritis." Scand. J. Rheumatol. Suppl. 65:81-4, Review.	
	1	9 Specification of US Patent No. RE 36,547.	
	1		
	1		

Examiner Considered \*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, No. 20231. Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

Complete if Known			
Application Number	10/037,791		
Filing Date	January 3, 2002		
First Named Inventor	Stanley M. Crain		
Art Unit	1614		
Examiner Name	James H. Reamer		
Attorney Docket Number	96700/727		

			U.S. PATI	ENT DOCUMENTS	
Examiner Initials	No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	20 21 22 23 24	us- 4,582,835 us- 3,879,555 us- 4,935,428 us- 5,834,477 us- 4,863,928	4/15/86 4/22/75 6/19/90 11/10/98 9/5/89	Lewis, et al. Pachter, et al. Lewis, et al. Mioduszewski Atkinson, et al.	
		US- US- US- US- US-			
		us- us- us-			·
	,	us- us- us-			· · · · · · · · · · · · · · · · · · ·
		us- us- us-			· · · · · · · · · · · · · · · · · · ·
		US-			

FOREIGN PATENT DOCUMENTS								
Examiner Initiats	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> "Number <sup>4</sup> - Kind Code <sup>3</sup> (if known)	Publication Date	Name of Palentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
		and the same of th						
******				« )				
		0	·					
			<b>.</b>					
			· ·					
				• • • • • • • • • • • • • • • • • • •				

Examiner	Date	
	Date	<u> </u>
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Uraw line through citation in not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional).

2 See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04.

3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

6 Applicant is to place a check mark here if English language Translation is attached. English language Translation is attached.